2012
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. Journal Of The National Cancer Institute 2012, 104: 228-239. PMID: 22247021, PMCID: PMC3274509, DOI: 10.1093/jnci/djr523.Peer-Reviewed Original ResearchMeSH KeywordsAspartic AcidCarcinoma, Non-Small-Cell LungCell Line, TumorClinical Trials, Phase II as TopicCysteineDisease-Free SurvivalGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, rasGenetic VectorsGlycineHumansImmunoblottingImmunoprecipitationKaplan-Meier EstimateLentivirusLung NeoplasmsMicroarray AnalysisMolecular Targeted TherapyMutationProto-Oncogene Proteins c-aktRandomized Controlled Trials as TopicSignal TransductionTOR Serine-Threonine KinasesTreatment OutcomeValineConceptsNon-small cell lung cancerKirsten rat sarcoma viral oncogene homologProgression-free survivalNSCLC cell linesWild-type KrasMutant KrasRefractory non-small cell lung cancerWorse progression-free survivalRat sarcoma viral oncogene homologRas2 Kirsten rat sarcoma viral oncogene homologSarcoma viral oncogene homologKaplan-Meier curvesCell lung cancerReverse-phase protein array studiesKRas proteinsHuman bronchial epithelial cellsCancer cell growthPatient tumor samplesCell linesImmortalized human bronchial epithelial cellsBronchial epithelial cellsProtein array studiesTumor gene expressionEvaluable patientsClinical outcomes
2002
Assessment of Antiangiogenic Effect Using 99mTc-EC-Endostatin
Yang DJ, Kim KD, Schechter NR, Yu DF, Wu P, Azhdarinia A, Roach JS, Kalimi SK, Ozaki K, Fogler WE, Bryant JL, Herbst R, Abbruzzes J, Kim EE, Podoloff DA. Assessment of Antiangiogenic Effect Using 99mTc-EC-Endostatin. Cancer Biotherapy & Radiopharmaceuticals 2002, 17: 233-246. PMID: 12030117, DOI: 10.1089/108497802753773856.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCollagenCysteineEndostatinsEndothelial Growth FactorsFemaleFibroblast Growth Factor 2In Situ Nick-End LabelingIntercellular Signaling Peptides and ProteinsInterleukin-8LymphokinesMammary Neoplasms, ExperimentalNeovascularization, PathologicPaclitaxelPeptide FragmentsRadionuclide ImagingRatsRats, Inbred F344TechnetiumTumor Cells, CulturedVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsTumor-bearing ratsAnti-angiogenesis therapyTreatment responseTumor uptakeTUNEL assayAnti-angiogenic treatment responseTumor vascular densityIL-8 expressionTumor-bearing animal modelsCount density ratiosCell viabilityPrognostic indicatorMicrovessel densityVascular densityAnimal modelsEndostatin therapyAntiangiogenic effectsMetastatic potentialTherapyUptake doseCellular uptake assaysEndostatinTissue distributionRatsEthylenedicysteine